# Alamar Biosciences, Inc. (ALMR)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/alamar-biosciences-inc/ JSON: https://steadybase.io/company/alamar-biosciences-inc.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Alamar Biosciences, Inc.
- Ticker: ALMR (Nasdaq)
- SEC CIK: 0002104204
- Industry: Laboratory Analytical Instruments (SIC 3826)
- Headquarters: Fremont, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: alamarbio.com
- Investor relations: https://alamarbio.com/company/investors/
- LinkedIn: https://www.linkedin.com/company/alamar-biosciences-inc
- Next earnings date: Nov 9, 2026

## Key facts

- Shares outstanding: 69,481,651 as of Oct 31, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526445905/0001193125-26-445905-index.html

## Business

We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2104204/000119312526161647/d39680d424b4.htm

## Officers and directors

- Justin J. McAnear, Chief Financial Officer. Source: Form 4 filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/2104204/000178638626000006/0001786386-26-000006-index.htm
- Shiping Chen, Chief Operating Officer. Source: Form 4 filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/2104204/000212694426000004/0002126944-26-000004-index.htm
- Timothy Ogden White, President. Source: Form 4 filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/2104204/000212670426000004/0002126704-26-000004-index.htm
- Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. LinkedIn: https://linkedin.com/in/yuling-luo-9216a5. Source: 8-K filed Nov 3, 2026, https://www.sec.gov/Archives/edgar/data/2104204/000119312526445353/ck0002104204-ex99_1.htm
- John L. Brottem, General Counsel. LinkedIn: https://linkedin.com/in/john-brottem. Source: Form 4 filed Sep 16, 2026, https://www.sec.gov/Archives/edgar/data/2104204/000182338126000014/0001823381-26-000014-index.htm

## Recent 8-K events

- Nov 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526445353/ck0002104204-20261030.htm
- Sep 1, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526378360/d262303d8k.htm
- Aug 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/ck0002104204-20260810.htm
- Jul 15, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526304736/d112405d8k.htm
- May 8, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/ck0002104204-20260508.htm
- Apr 20, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526163921/d103481d8k.htm

## Insider trades (Form 4)

- Apr 20, 2026: Nicholas Naclerio (Director) bought 235,294 shares, about $4.0M. Source: https://www.sec.gov/Archives/edgar/data/2104204/000153416626000006/0001534166-26-000006-index.htm

## What management said

- "Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time" Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences (8-K filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526445353/ck0002104204-ex99_1.htm
- "Tod has been an outstanding partner and leader during a pivotal period for Alamar" Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences (8-K filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/2104204/000119312526445353/ck0002104204-ex99_1.htm

## Latest filings

- 8-K filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/2104204/000119312526445353/ck0002104204-20261030.htm
- 10-Q filed Aug 11, 2026: https://www.sec.gov/Archives/edgar/data/2104204/000119312526343003/ck0002104204-20260630.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/